AUDA (CAS 479413-70-2)
See product citations (1)
QUICK LINKS
AUDA is an inhibitor of soluble epoxide hydrolase (sEH, IC50 = 18 nM in mice). At a concentration of 10 μM, AUDA is able to activate peroxisome proliferator-activated receptor α (PPARα) 3-fold, while showing no ability to affect PPARδ or PPARγ. It has found utility in various applications, both in vitro and in vivo. In vitro studies have utilized Auda to investigate the impact of its inhibition on cellular processes such as proliferation, gene expression, and protein synthesis. The mechanism of action of Auda involves the inhibition of the enzyme cyclooxygenase (COX), which plays a key role in catalyzing the conversion of arachidonic acid into prostaglandins and other bioactive lipids. Through this enzymatic inhibition, Auda diminishes the synthesis of prostaglandins, which are known to contribute to processes like inflammation and pain.
AUDA (CAS 479413-70-2) References
- Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. | Morisseau, C., et al. 2002. Biochem Pharmacol. 63: 1599-608. PMID: 12007563
- Cytochrome P450 epoxygenases as EDHF synthase(s). | Fleming, I. 2004. Pharmacol Res. 49: 525-33. PMID: 15026030
- Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. | Fang, X., et al. 2005. J Pharmacol Exp Ther. 314: 260-70. PMID: 15798002
- An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. | Imig, JD., et al. 2005. Hypertension. 46: 975-81. PMID: 16157792
- An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. | Dorrance, AM., et al. 2005. J Cardiovasc Pharmacol. 46: 842-8. PMID: 16306811
- Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. | Li, J., et al. 2008. Front Biosci. 13: 3480-7. PMID: 18508449
- Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases. | Zhang, J., et al. 2015. Pharmazie. 70: 24-8. PMID: 25975094
- Ingestion of the epoxide hydrolase inhibitor AUDA modulates immune responses of the mosquito, Culex quinquefasciatus during blood feeding. | Xu, J., et al. 2016. Insect Biochem Mol Biol. 76: 62-69. PMID: 27369469
- Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways. | Dong, XW., et al. 2017. Toxicology. 389: 31-41. PMID: 28694203
- The weakening effect of soluble epoxide hydrolase inhibitor AUDA on febrile response to lipopolysaccharide and turpentine in rat. | Piotrowski, J., et al. 2017. J Physiol Biochem. 73: 551-560. PMID: 28741242
- Vascular repair and anti-inflammatory effects of soluble epoxide hydrolase inhibitor. | Dai, N., et al. 2019. Exp Ther Med. 17: 3580-3588. PMID: 30988740
- Soluble epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, represses human aortic smooth muscle cell proliferation and migration by regulating cell death pathways via the mTOR signaling. | Li, SH., et al. 2017. Int J Clin Exp Pathol. 10: 8434-8442. PMID: 31966695
- Multimodal Optical Imaging to Investigate Spatiotemporal Changes in Cerebrovascular Function in AUDA Treatment of Acute Ischemic Stroke. | Wang, HL., et al. 2021. Front Cell Neurosci. 15: 655305. PMID: 34149359
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AUDA, 5 mg | sc-221276 | 5 mg | $49.00 | |||
AUDA, 10 mg | sc-221276A | 10 mg | $84.00 |